What You Should Know Before Getting Stem Cell Therapy | Consumer Guide

Stem cell therapy is one of the most promising - and most overhyped - areas of modern medicine. Thousands of clinics now offer some version of it, and the price tag can run anywhere from $3,000 to $25,000 per treatment. The problem? Not all of these clinics are offering what they claim.

The FDA has issued multiple consumer alerts about unproven stem cell products, and the 9th Circuit Court of Appeals ruled in 2024 that the agency can regulate clinics offering unapproved therapies. Adverse events - including infections, blindness, and tumors - have been linked to unregulated treatments.

This does not mean stem cell therapy is a scam. When performed correctly, using the right cell source, precise delivery, and honest patient selection, regenerative treatments can produce meaningful results for joint pain, soft tissue injuries, and certain degenerative conditions.

The difference between a good outcome and a wasted $10,000 often comes down to five questions. Here is exactly what to ask - and what the answers should sound like.

Question 1: "Where Do the Cells Come From?"

What you want to hear: "They come from your own body" - specifically, bone marrow aspirate concentrate (BMAC) from the iliac crest, or adipose (fat) tissue.

This is the most important question you will ask. The cell source determines whether you are receiving a treatment backed by scientific rationale or a product with questionable viability.

Autologous cells - meaning your own - are the FDA-compliant standard for stem cell procedures when performed as a same-day, minimal-manipulation procedure. Your bone marrow and fat tissue contain living mesenchymal stem cells (MSCs) that can be harvested, concentrated, and re-injected in a single visit.

If a clinic says they use "umbilical cord," "placenta," "amniotic fluid," or "Wharton's Jelly" products, you need to ask a follow-up question: are there actually living stem cells in the product? Research published in the American Journal of Sports Medicine tested five commercially available umbilical cord products that all claimed to contain live MSCs. The findings were definitive - none of the products contained viable, functional stem cells after the standard thawing process [Source: Berger et al., AJSM, 2025].

The reason is straightforward: the supply chain for birth-tissue products involves harvesting, processing, freezing, shipping, storing, and then rapid "shock thawing" at the clinic. This chain of events kills the cells. The products may contain growth factors and cytokines - which have some short-term anti-inflammatory value - but calling them "stem cell therapy" is misleading.

RED FLAG: Any clinic charging $5,000+ for an "umbilical cord stem cell injection" while implying it contains living stem cells is, at best, misinformed - and at worst, deliberately misleading you.

Question 2: "Do You Use Image Guidance for the Injection?"

What you want to hear: "Yes, we always use fluoroscopy (live X-ray) or ultrasound guidance."

This question separates serious regenerative medicine practices from those cutting corners.

A systematic review of Level I randomized controlled trials (the highest quality of evidence) found that ultrasound-guided knee injections achieved greater than 95% accuracy across every anatomical approach. Blind injections? Accuracy ranged from 77% to 96% depending on the approach, with inexperienced practitioners missing the target in up to 21% of cases [Source: Saha et al., J Funct Morphol Kinesiol, 2023; Arthroscopy Sports Med Rehabil, 2021].

For smaller or deeper joints - hips, ankles, shoulders - the miss rate for blind injections climbs even higher. One study reported blind ankle injection accuracy as low as 63% [Source: Ramesh et al., as cited in Saha et al., 2023].

Think about what this means practically. You are paying thousands of dollars for a biologic product derived from your own bone marrow. If it is injected into the soft tissue surrounding the joint instead of into the joint space itself, you have functionally wasted your money. A 2019 study found that patients receiving ultrasound-guided hyaluronic acid injections had a significantly lower rate of conversion to knee replacement surgery over a decade - 33% versus 46% for those injected blindly [Source: Park et al., J Clin Ultrasound, 2012].

RED FLAG: If a provider says they inject "by feel" or that image guidance "isn't necessary for large joints," that is a warning sign. The research is clear: guidance improves accuracy regardless of joint size, and the cost of the equipment is minimal compared to the cost of your treatment.

Question 3: "Do You Process the Cells at the Bedside or Send Them Out?"

What you want to hear: "We process them here at the bedside or in-house lab, and re-inject the same day."

This is a regulatory and safety question rolled into one.

Under current FDA regulations, autologous stem cell procedures that qualify as "same surgical procedure" - meaning the cells are harvested, minimally processed, and re-injected in the same clinical encounter - operate within established guidelines. The cells are not classified as a drug in this context.

If a clinic sends your cells to an outside lab for "culturing" or "expansion" over days or weeks, the product is now classified as a biologic drug under FDA rules. This requires an Investigational New Drug (IND) application and clinical trial oversight. Without that, the clinic is operating outside FDA guidelines [Source: FDA Consumer Alert on Regenerative Medicine Products, 2022; 9th Circuit ruling, California Stem Cell Treatment Center v. FDA, 2024].

A legitimate same-day procedure typically looks like this: you arrive, the physician harvests bone marrow from your iliac crest (back of the pelvis), the sample is processed in a centrifuge to concentrate the stem cells, and the concentrate is re-injected under image guidance - all within a few hours.

RED FLAG: Any mention of "growing" or "multiplying" your cells over multiple days, shipping your cells to a lab, or receiving cells back at a later appointment. Unless the clinic is running an FDA-registered clinical trial, this violates current regulatory standards.

Question 4: "Am I Actually a Good Candidate, or Is My Condition Too Severe?"

What you want to hear: An honest assessment. Including the possibility that you may need surgery instead.

Stem cell therapy generally works best for mild-to-moderate osteoarthritis (Kellgren-Lawrence Grade 2-3) and partial soft tissue injuries where some structural integrity remains. The biological logic is sound: you are introducing concentrated repair cells into an area where the body's natural healing process has stalled but where the tissue architecture is not completely destroyed.

The critical distinction is between "degenerated but repairable" and "bone-on-bone." In severe Grade 4 osteoarthritis, where cartilage is essentially gone and bone is grinding on bone, stem cells do not have a scaffold to work with. No credible evidence supports the claim that stem cells can "regrow" cartilage in a joint that has reached end-stage degeneration.

An ethical provider will review your imaging, assess your functional status, and tell you directly if you have passed the point where regenerative therapy is likely to help. The honest answer is sometimes: "You are a candidate for a total joint replacement, and spending money on stem cells would delay the treatment you actually need."

RED FLAG: A clinic that promises to "regrow cartilage" in a bone-on-bone knee, or that tells every patient they are a candidate regardless of severity. If no one is ever told "this won't work for you," the clinic is selling, not treating.

Question 5: "Who Performs the Actual Harvest and Injection?"

What you want to hear: "The MD or DO performs the procedure personally."

Bone marrow aspiration is an invasive procedure. It involves inserting a needle through the posterior iliac crest into the marrow cavity. Precision matters - both for patient safety and for the quality of the aspirate collected. The practitioner needs to understand aspiration technique to obtain a high concentration of stem cells rather than just peripheral blood.

In some "wellness" clinic models, a salesperson sells the treatment package and a mid-level provider - nurse practitioner or physician assistant - performs the actual procedure. While NPs and PAs are skilled professionals in their scope, a bone marrow aspiration followed by image-guided injection into a specific joint space is a procedure that warrants a physician with training in musculoskeletal medicine, pain management, or orthopedics.

Ask specifically: Who harvests the bone marrow? Who operates the fluoroscopy or ultrasound during injection? Is it the same physician, or are different people handling different parts?

RED FLAG: If you cannot meet the physician who will perform your procedure before committing financially, or if the consultation is conducted entirely by a non-physician "patient coordinator" focused on closing the sale.

Three Bonus Questions That Show You Have Done Your Research

If you want to go further, these additional questions will immediately signal to the provider that you are an informed consumer:

"What is your cell count after processing?" A quality bone marrow concentrate should yield a documented cell count. Clinics that cannot tell you the approximate number of nucleated cells or MSCs in your concentrate are not tracking the quality of what they are injecting.

"Do you have outcome data from your own patients?" Any clinic that has been performing stem cell procedures for more than a year should be tracking patient outcomes - pain scores, functional improvement, imaging follow-up. If they have no data, they are not measuring whether their treatment works.

"What happens if it does not work?" An honest clinic will tell you that regenerative treatments do not work for everyone. Ask what the expected success rate is for your specific condition and what the follow-up plan looks like if results are suboptimal.

Why These Questions Matter

The regenerative medicine field is at a crossroads. Legitimate science supports the use of autologous stem cells for specific musculoskeletal conditions. Peer-reviewed clinical trials show measurable improvements in pain and function for appropriately selected patients. The FDA has approved specific cell and gene therapies, and the pipeline is growing - with new approvals in 2024-2025 for conditions ranging from sickle cell disease to graft-versus-host disease.

At the same time, an entire industry has sprung up around selling unproven products to desperate patients. The FTC and FDA have both taken enforcement action against clinics making false claims. The 9th Circuit's 2024 ruling reinforced that clinics cannot circumvent FDA oversight by calling their products "same surgical procedure" when they clearly involve more-than-minimal manipulation.

You deserve to know what you are paying for. These five questions - asked directly, in the consultation, before any money changes hands - will separate the credible providers from the rest.

How We Approach Stem Cell Therapy at Regenesis MD

At Regenesis MD in Raleigh, Dr. Bhavna Vaidya practices regenerative medicine with full transparency. Here is how we answer each of these questions for our own patients:

• Cell source: We use your own bone marrow-derived stem cells (BMAC), harvested from the iliac crest. We do not sell umbilical cord products as "stem cell therapy."
• Image guidance: Every injection is performed under fluoroscopy or ultrasound guidance. No blind injections.
• Processing: All cell processing is done same-day, in-office. Your cells never leave the building.
• Candidacy: We turn away patients who are not appropriate candidates. If your condition is too severe for regenerative therapy, we will tell you directly and discuss surgical referral options.
• Practitioner: Dr. Vaidya personally performs every harvest and injection. You meet your physician before any financial commitment.

References & Sources

• FDA Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. July 22, 2022. U.S. Food and Drug Administration.
• Saha P, Smith M, Hasan K. Accuracy of Intraarticular Injections: Blind vs. Image Guided Techniques. J Funct Morphol Kinesiol. 2023;8(3):93.
• Ultrasound-Guided Knee Injections Are More Accurate Than Blind Injections: A Systematic Review of Randomized Controlled Trials. Arthrosc Sports Med Rehabil. 2021;3(4):e1177-e1187.
• Berger D, et al. Analysis of Commercially Available Umbilical Cord Stem Cell Products. Am J Sports Med. 2025.
• California Stem Cell Treatment Center v. FDA. 9th U.S. Circuit Court of Appeals. September 2024.
• Knoepfler P. Updated 2025 List of FDA-Approved Cell and Gene Therapies. The Niche (ipscell.com). December 2025.

Medical Disclaimer: This content is for educational purposes and does not constitute medical advice. Stem cell therapy outcomes vary by individual. The procedures described at Regenesis MD use autologous cells in same-day, minimally-manipulated protocols. These procedures have not been evaluated or approved by the FDA for specific disease treatment. Consult with a qualified physician to determine if you are a candidate. Results are not guaranteed.